Evaluating combined bevacizumab and XELOX in advanced colorectal cancer: Serum markers carcinoembryonic antigen, carbohydrate antigen 125, carbohydrate antigen 199 analysis

doi:10.12998/wjcc.v12.i1.15

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1149)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

WORD

HTML

618

Figures (1-2)

109

Tables (1-4)

113

Sum=880

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

162

Sum=218

Jan 6, 2024 (publication date) through May 12, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Clin Cases. Jan 6, 2024; 12(1): 15-23
Published online Jan 6, 2024. doi: 10.12998/wjcc.v12.i1.15

Open in New Tab Full Size Figure Download Figure

Figure 1 Serum tumor marker levels of carcinoembryonic antigen, carbohydrate antigen 199 and carbohydrate antigen 125 in the control and observation groups. ^aP < 0.05 and ^bP < 0.001.

Open in New Tab Full Size Figure Download Figure

Figure 2 Progression-free survival of metastatic colorectal cancer patients in the control and observation groups. ^bP < 0.001. PFS: Progression-free survival.

Citation: Zhou DB, Cheng J, Zhang XH. Evaluating combined bevacizumab and XELOX in advanced colorectal cancer: Serum markers carcinoembryonic antigen, carbohydrate antigen 125, carbohydrate antigen 199 analysis. World J Clin Cases 2024; 12(1): 15-23
URL: https://www.wjgnet.com/2307-8960/full/v12/i1/15.htm
DOI: https://dx.doi.org/10.12998/wjcc.v12.i1.15